Preliminary Evaluation of Septin9 in Patients With Hereditary Colon Cancer Syndromes (Septin9)
Sponsor: Epigenomics, Inc
A observational or N/A phase clinical study on Colorectal Cancer and Familial Adenomatous Polyposis, this trial is completed. The trial is conducted by Epigenomics, Inc and has accumulated 13 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Dec 2021 — Jul 2024 [monthly]
Completed
-
Jan 2021 — Dec 2021 [monthly]
Completed
-
Nov 2020 — Jan 2021 [monthly]
Completed
▶ Show 8 earlier versions
-
Sep 2019 — Nov 2020 [monthly]
Completed
Status: Recruiting → Completed
-
Mar 2019 — Sep 2019 [monthly]
Recruiting
-
Jun 2018 — Mar 2019 [monthly]
Recruiting
-
May 2018 — Jun 2018 [monthly]
Recruiting
-
Apr 2018 — May 2018 [monthly]
Recruiting
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Recruiting NA
-
Feb 2017 — Aug 2017 [monthly]
Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Recruiting NA
First recorded
Jul 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Epigenomics, Inc
- University of Pennsylvania
For direct contact, visit the study record on ClinicalTrials.gov .